Document:

Exhibit
10.23

 

AMENDMENT
NO. 1 TO FINANCING AGREEMENT

 

THIS
AMENDMENT TO FINANCING AGREEMENT (the “Amendment”) is made and executed on the 13 day of October, 2021, by and between
Holisto Ltd (the “Company” or “Borrower”), a company organized under the laws of the State of Israel
(Company No. 51-534153-5), whose address is 2 Nim Blvd., Rishon Lezion, and Discount Capital Ltd (the “Lender”), a
company organized under the laws of the State of Israel (Company No. 51-171425-5), whose address is Rothschild 22, Tel Aviv.

 

W
I T N E S S E T H:

 

WHEREAS,
the Company and Lender entered into that certain financing agreement dated as of March 25, 2021 (the “Financing Agreement”)
pursuant to which Lender has extended the Company Loans in the aggregate principal amount of US$ 4,000,000; and

 

WHEREAS,
the Company has requested that the Lender shall make available to the Company, as of the New Loan Closing (as defined below) or further
thereafter (as further provided herein), and subject to the fulfillment of the conditions precedent provided therefor hereunder, additional
loans (the “New Loans”) in an aggregate principal amount not to exceed the Maximum New Loan Amount (as defined below),
subject to the terms and conditions set forth herein; and

 

WHEREAS,
the Lender has agreed to make such New Loans available to the Company in accordance with and subject to the terms of the Financing Agreement
as amended hereby and in return, among others, for the receipt, in consideration for the benefits conferred upon the Company hereunder,
of the New Warrant (as defined below) and (if applicable in accordance with the provisions of the New Warrant) the Additional New Warrant
(as defined in the New Warrant), all on the terms and conditions set forth in the Financing Agreement as amended hereby.

 

NOW
THEREFORE, the parties hereto hereby agree as follows:

 

		1.	Definitions
                                            and Interpretation

 

		1.1.	Capitalized
                                            terms used but not defined herein shall have the meanings ascribed thereto under the Financing
                                            Agreement. In this Amendment the following terms shall have the respective meanings ascribed
                                            thereto:

 

	“Additional
    Management Fee”	-	shall have
    the meaning ascribed thereto under Section ‎6.1 below.
	 	 	 
	“Amended and Restated
    AOA”	-	shall have the meaning
    ascribed thereto under Section ‎3.2.1 below.
	 	 	 
	“Compliance Certificate”	 	a duly completed compliance
    certificate, in the form attached hereto as Exhibit 1.1(a), signed by the CEO or CFO of the Company.
	 	 	 
	“Disbursement
    Compliance Certificate”	 	a duly completed compliance
    certificate, in the form attached hereto as Exhibit 1.1(b), signed by the CEO or CFO of the Company.
	 	 	 

 

	“Disbursement
    Conditions”	-	all of the following conditions
    (a) providing Lender with the applicable Disbursement Request in compliance with the provisions hereof which shall be accompanied
    by a Disbursement Compliance Certificate, (b) no Default exists at the time of the Disbursement Request or the applicable New Installment
    Date, (c) no Default shall occur as a result of extension of the applicable New Loan, and (d) Lender shall have been provided with
    all documents (in original form) required for the due registration of all security interest created in relation to the Collateral
    hereunder, as required to be registered with any applicable Governmental Authority.

 

    

     

    

 

	 	 	 
	“Disbursement
        Request”

     

    
	-	a
disbursement request in the form attached hereto as Exhibit 1.1(c). Each Disbursement Request: (i) shall be duly executed
by the Company’s Chief Financial Officer and shall state the exact amount that the Company wishes to draw, provided that
such amount, together with the aggregate amounts previously drawn (whether or not prepaid) pursuant to this Amendment, shall not exceed
the Maximum New Loan Amount.

    

	 	 	 
	“Final
    Maturity Date”	 	Shall
    mean March 25, 2024.
	 	 	 
	“Maximum New Loan
    Amount”	-	US$ 3,000,000 which consists
    of the New Primary Loan and the New Expansion Loan.
	 	 	 
	“New Accounts
    Pledge Debenture”	-	shall have the meaning
    ascribed thereto under Section ‎3.2.1 below.
	 	 	 
	“New Company Charge
    Agreements”	-	shall have the meaning
    ascribed thereto under Section ‎3.2.1 below.
	 	 	 
	“New Expansion
    Loan”	-	shall have the meaning
    ascribed thereto under Section ‎2.2.1 below.
	 	 	 
	“New Expansion
    Loan Amount”	-	shall have the meaning
    ascribed thereto under Section ‎2.2.1 below.
	 	 	 
	“New Expansion
    Loan Availability Period”	-	shall have the meaning
    ascribed thereto under Section ‎2.2.2 below.
	 	 	 
	“New Expansion
    Loan Disbursement Date”	-	shall mean the actual date
    of extension of the New Expansion Loan in accordance with Section ‎2.2.2 below and the provisions hereof.
	 	 	 
	“New Floating
    Charge Debenture”	-	shall have the meaning
    ascribed thereto under Section ‎3.2.1 below.
	 	 	 
	“New Installment
    Date”	-	the date of actual extension
    of each New Loan in accordance with the provisions hereof.
	 	 	 
	“New IP Pledge
    Debenture”	-	shall have the meaning
    ascribed thereto under Section ‎3.2.1 below.
	 	 	 
	“New IP Security
    Agreement”	-	shall have the meaning
    ascribed thereto under Section ‎3.2.1 below.
	 	 	 
	“New Israeli Security
    Documents”	-	shall have the meaning
    ascribed thereto under Section ‎3.2.1 below.
	 	 	 

 

    -2-

     

    

 

	“New Loan Additional
    Cushion Deposit Amount”	-	shall have the meaning
    ascribed thereto under Section ‎2.4.2 below.
	 	 	 
	“New Loan Amortization
    Schedule”	-	shall have the meaning
    ascribed thereto under Section ‎2.1.3 below.
	 	 	 
	“New Loan Amount”	-	shall have the meaning
    ascribed thereto under Section ‎2.5 below.
	 	 	 
	“New Loan Basic
    Cushion Deposit Amount”	-	shall have the meaning
    ascribed thereto under Section ‎2.4.2 below.
	 	 	 
	“New Loan Closing”	-	shall have the meaning
    ascribed thereto under Section ‎3.1 below.
	 	 	 
	“New Loan Closing
    Date”	-	shall have the meaning
    ascribed thereto under Section ‎3.1 below.
	 	 	 
	“New Loan Interest”	-	shall have the meaning
    ascribed thereto under Section ‎2.6.1 below.
	 	 	 
	“New Loan Interest
    Payment Date”	-	(i) October 31, 2021, (ii)
    the last Business Day of each calendar month thereafter, until (but not including) the calendar month during which the Final
    Maturity Date occurs, and (iii) the Final Maturity Date.
	 	 	 
	“New Loan Interest
    Period”	-	the period commencing on
    the first day following any New Loan Interest Payment Date and ending on the subsequent New Loan Interest Payment Date, provided
    that (i) with respect to the New Primary Loan – the first New Loan Interest Period shall commence on the New Loan Closing
    Date and end on the first New Loan Interest Payment Date to occur thereafter, and (ii) with respect to the New Expansion Loan (to
    the extent extended) – the first New Loan Interest Period shall commence on the New Expansion Loan Disbursement Date and end
    on the later of (1) the first New Loan Interest Payment Date to occur thereafter, and (2) December 31, 2021. 
	 	 	 
	“New Loan Prepayment
    Fee”	-	shall have the meaning
    ascribed thereto under Section ‎2.8.1 below.
	 	 	 
	“New Loan Principal
    Payment Date”	-	shall have the meaning
    ascribed thereto under Section ‎2.1.3 below.
	 	 	 
	“New Primary Loan”	-	shall have the meaning
    ascribed thereto under Section ‎2.1.1 below.
	 	 	 
	“New Primary Loan
    Amount”	-	shall have the meaning
    ascribed thereto under Section ‎2.1.1 below.

 

    -3-

     

    

 

	 	 	 
	“New Secured Amounts”	-	shall mean all amounts
    due or which may become due to Lender under or in connection with the New Transaction Agreements (including principal, interest,
    fees and any other amounts accrued or which may accrue thereon or due or which may become due in connection therewith).
	 	 	 
	“New Security
    Documents”	-	the New Company Charge
    Agreements, the Guarantees (if any), the Negative Pledges (if any) and all documents ancillary thereto or otherwise executed in connection
    therewith.
	 	 	 
	“New Transaction
    Agreements”	 	collectively, this Amendment,
    the New Security Documents, the New Warrant, the Additional New Warrant (if applicable), each Compliance Certificate, Disbursement
    Compliance Certificate and Disbursement Request, together with any other document ancillary hereto or thereto, or otherwise executed
    and delivered in connection herewith or therewith, each as may be amended from time to time.
	 	 	 
	“New Warrant”	-	shall have the meaning
    ascribed thereto under Section ‎3.2.1 below.
	 	 	 
	“New Warrant Shares”	-	shall have the meaning
    ascribed thereto under Section ‎4.1.1 below.
	 	 	 
	“Non-Utilization
    Fee”	-	shall have the meaning
    ascribed thereto under Section ‎2.7 below.
	 	 	 
	“Required Consents
    and Approvals”	-	all the waivers, notifications,
    consents and approvals required to be obtained by the Company and/or any Guarantor with respect to the New Transaction Agreements
    and the transactions contemplated therein, all of which are listed in Exhibit 1.1(d) hereto.
	 	 	 
	“One Time Fee”	-	shall have the meaning
    ascribed thereto under Section ‎6.2 below.
	 	 	 
	“Unutilized Portion”	-	shall have the meaning
    ascribed thereto under Section ‎2.7 below.

 

		1.2.	In
                                            addition, certain defined terms used in the Financing Agreement shall be deemed amended as
                                            provided herein below:

 

		1.2.1.	The
                                            term ‘Collateral’ shall include also all assets of Borrower covered by the New
                                            Security Documents.

 

		1.2.2.	The
                                            term ‘Secured Amounts’ shall include also the New Secured Amounts.

 

		1.2.3.	The
                                            term ‘Security Documents’ shall include also the New Security Documents.

 

		1.2.4.	The
                                            term ‘Transaction Agreements’ shall include also the New Transaction Agreements.

 

		1.3.	The
                                            term ‘Initial Cushion Deposit Amount’ appearing in Section 8.1.2 of the Financing
                                            Agreement shall be replaced with the term ‘Basic Cushion Deposit Amount’, and
                                            references to ‘Transaction Documents’ appearing in the Financing Agreement shall
                                            be replaced with references to ‘Transaction Agreements’.

 

    -4-

     

    

 

		2.	The
                                            New Loans

 

		2.1.	New
                                            Primary Loan.

 

		2.1.1.	Loan
                                            Amount. Subject to the terms and conditions, and on the basis of the representations
                                            and warranties, set forth herein and in the Financing Agreement (as amended hereby), the
                                            Lender has agreed to provide the Company, at the New Loan Closing and subject to the fulfillment
                                            of the conditions precedent therefor as provided hereunder, with a loan at the principal
                                            amount of One and a Half Million Dollars (US$1,500,000) (the “New Primary Loan”
                                            and “New Primary Loan Amount”, respectively).

 

		2.1.2.	Disbursement.
                                            The Lender shall extend the New Primary Loan to the Company on the New Loan Closing Date,
                                            subject to satisfaction of all Disbursement Conditions and to the occurrence of New Loan
                                            Closing in accordance with the provisions hereof, to the Lender’s satisfaction.

 

		2.1.3.	Principal
                                            Payments. Subject to the Acceleration set out under the Financing Agreement (which apply
                                            hereto, mutatis mutandis, as provided below) and the Prepayment provisions set forth
                                            below, the principal of the New Primary Loan shall be repaid as follows (each, a “New
                                            Loan Principal Payment Date”):

 

		(a)	27
                                            equal monthly payments each in an amount equal to US$ 53,570, commencing on the Interest
                                            Payment Date to occur at the end of December 2021 and ending on the latest Interest Payment
                                            Date to occur prior to the Final Maturity Date; and

 

		(b)	the
                                            remaining unpaid balance of the principal amount of the New Primary Loan (if any) shall be
                                            made on the Final Maturity Date,

 

all
in accordance with the amortization schedule provided by Lender to Borrower in accordance with the foregoing, as may be updated from
time to time by Lender solely to reflect to the provisions hereof (the “New Loan Amortization Schedule”).

 

		2.2.	New
                                            Expansion Loan.

 

		2.2.1.	Loan
                                            Amount. Subject to the terms and conditions, and on the basis of the representations
                                            and warranties, set forth herein and in the Financing Agreement (as amended hereby), the
                                            Lender has agreed to provide the Company, with an additional loan at the principal amount
                                            of US$ 1,500,000 (the “New Expansion Loan” and “New Expansion
                                            Loan Amount”, respectively).

 

		2.2.2.	Disbursement.
                                            The Lender shall extend the New Expansion Loan to the Company as soon as possible and not
                                            more than within five (5) Business Days of the official public announcement by Moringa Acquisition
                                            Corp, a corporation publically traded on NASDAQ, of the signing of definitive agreement for
                                            merger with the Company (the “Merger Announcement” and “SPAC
                                            Merger”, respectively) – subject to satisfaction of all Disbursement Conditions
                                            to the Lender’s good faith business judgment, provided that if the Merger Announcement
                                            shall not be made during the first 6 months following the New Loan Closing Date (the “New
                                            Expansion Loan Availability Period”), the New Expansion Loan shall no longer be
                                            available for drawing by the Company.

 

		2.2.3.	Principal
                                            Payments. Subject to the Acceleration provisions set out under the Financing Agreement
                                            (which apply hereto, mutatis mutandis, as provided below) and the Prepayment provisions
                                            set forth below, the principal of the New Extension Loan shall be repaid in equal monthly
                                            installments, each in an amount equal to the New Extension Loan Amount divided by the number
                                            of remaining New Loan Interest Payment Dates following the New Extension Loan Disbursement
                                            Date, commencing on the later of (i) the first New Loan Principal Payment Date to occur following
                                            the New Expansion Loan Disbursement Date, and (ii) December 31, 2021, and ending on the Final
                                            Maturity Date, all in accordance with the updated New Loan Amortization Table to be provided
                                            by Lender to Borrower upon extension of the New Expansion Loan which shall reflect to above
                                            provisions.

 

    -5-

     

    

 

		2.3.	Purpose.
                                            The New Loans shall be used for funding the Company’s expenses incurred in relation
                                            to the SPAC Merger.

 

		2.4.	Extension
                                            of the New Loans.

 

		2.4.1.	Each
                                            New Loan shall be extended by the Lender to the Borrower as further described below, in U.S.
                                            Dollars, by means of a wire transfer of immediately available funds to the Borrower Bank
                                            Account.

 

		2.4.2.	On
                                            the New Loan Closing Date, subject to the provisions hereof, Lender shall extend in the Borrower
                                            Bank Account the New Primary Loan amount less (a) the transaction expenses
                                            due and payable as of the New Loan Closing Date in accordance with the terms hereof (i.e
                                            US$ 17,000), and (b) an amount of US$124,000 (the “New Loan Basic Cushion Deposit
                                            Amount”), which shall be deposited in the Cushion Deposit. The foregoing shall
                                            constitute extension of the entire New Primary Loan to Borrower in accordance with the provisions
                                            hereof. Borrower shall have no claims whatsoever in relation to the management of the Cushion
                                            Deposit by Lender.

 

For
sake of cautious, at the New Loan Closing Borrower shall create in favor of Lender an exclusive fixed ranking fixed pledge and assignment
by way of pledge, without limitation in amount, over any and all rights Borrower has (if any at all) in relation to the Cushion Deposit,
under the New Accounts Pledge Debenture (the “New Cushion Deposit Pledge”).

 

		2.4.3.	On
                                            the New Expansion Loan Disbursement Date, if applicable in accordance with and subject to
                                            the provisions hereof, Lender shall extend in the Borrower Bank Account the New Expansion
                                            Loan amount less an amount of US$140,000 (the “New Loan Additional
                                            Cushion Deposit Amount”), which shall be deposited in the Cushion Deposit and shall
                                            also be subject to the New Cushion Deposit Pledge. The foregoing shall constitute extension
                                            of the entire New Expansion Loan to Borrower in accordance with the provisions hereof.

 

		2.5.	New
                                            Loans Term. The term of each New Loan shall commence on the relevant New Installment
                                            Date and terminate upon repayment by the Company of the New Primary Loan Amount or New Expansion
                                            Loan Amount, as applicable (each, a “New Loan Amount”), and all amounts
                                            accrued thereon in full, in accordance with the provisions contained herein, but in no event
                                            later than the Final Maturity Date.

 

		2.6.	Interest;
                                            Payment of Interest.

 

		2.6.1.	The
                                            outstanding principal of the New Loans shall bear U.S. Dollar denominated interest at an
                                            annual rate equal to 7% (the “New Loan Interest”), provided that,
                                            without derogating from the provisions of Section 2.7 (Step-Up Interest; Arrears Interest)
                                            of the Financing Agreement (which apply hereto, mutatis mutandis, as provided below),
                                            and in addition thereto, if and so long as any amount on account of the outstanding principal
                                            of the New Loans is overdue, the New Loan Interest shall be at the same rate of the Interest
                                            (as defined under the Financing Agreement).

 

    -6-

     

    

 

		2.6.2.	All
                                            terms applicable to the Interest under the Financing Agreement (as amended hereby), including
                                            without limitation, the provisions of section 2.6 (excluding 2.6.1) of the Financing Agreement,
                                            shall apply to the New Loan Interest, mutatis mutandis. For the removal of any doubt,
                                            the term ‘Due Payments’ shall include all New Loan Interest (including Arrears
                                            Interest, Step-Up Interest and Make Whole Interest which may apply in relation to the New
                                            Loans, New Loan Interest and any other payment due hereunder to Lender) payments and any
                                            other payments due hereunder to Lender (including the One Time Fee, Additional Management
                                            Fee and Non-Utilization Fee).

 

		2.7.	Non-Utilization
                                            Fee. The Company shall pay the Lender, as of the New Loan Closing Date and until the
                                            earlier of (i) expiration of the New Expansion Loan Availability Period and (ii) the New
                                            Expansion Loan Disbursement Date, a non-utilization fee (the “Non-Utilization Fee”)
                                            at the amount equal to an annual rate of 2.5% of the unutilized portion of the New
                                            Expansion Loan Amount (whether or not Borrower may withdraw any amounts therefrom pursuant
                                            to the provisions hereof) during each calendar month (or any portion thereof), calculated
                                            on a daily basis (the “Unutilized Portion”), plus applicable VAT. The
                                            Non-Utilization Fee shall be payable on each New Loan Interest Payment Date following the
                                            New Loan Closing Date with respect to the Unutilized Portion during the then ending New Loan
                                            Interest Period.

 

		2.8.	Prepayment.
                                            Notwithstanding the provisions contained herein, the Company may prepay any amounts due to
                                            the Lender on account of the New Loans (the “New Loan Prepaid Amount”),
                                            at any time prior to the Final Maturity Date (provided that the Company shall use its commercially
                                            reasonable efforts that such prepayment shall be made on a New Loan Interest Payment Date),
                                            subject to payment of the New Loan Prepayment Fee applicable to the New Loan Prepaid Amount
                                            as provided below, provided that the Company delivers to Lender a written notice (“New
                                            Loan Prepayment Notice”) at least seven (7) days prior to the requested prepayment
                                            date, and provided, further, that the New Loan Prepaid Amount shall not be
                                            less than the lesser of (i) US$ 200,000 and (ii) all amounts then outstanding under the New
                                            Transaction Agreements on account of the New Loans.

 

For
the purposes hereof:

 

		2.8.1.	“New
                                            Loan Prepayment Fee” shall be an amount equal to the difference (as
                                            of the effective time of prepayment) between: (a) the future cash flow (principal plus New
                                            Loan Interest payments) in respect of the prepaid portion of the New Loans, discounted based
                                            on the Government Bond Yield (as defined below) plus 1.75% per year, and (b) the New Loan
                                            Prepaid Amount. New Loan Prepayment Fee shall in no event be negative.

 

		2.8.2.	“Government
                                            Bond Yield” shall mean the weighted average of the gross yield to maturity (before
                                            tax) stated as a percentage and rounded up to the nearest four places after the decimal point
                                            of two Reference Bonds, on the last five (5) trading days prior to the date of the New Loan
                                            Prepayment Notice (the last of such Business Days being the last Business Day before the
                                            date of the New Loan Prepayment Notice).

 

		2.8.3.	“Reference
                                            Bond” shall mean a bond denominated in NIS, issued by the State of Israel, traded
                                            on the Tel Aviv Stock Exchange, fully linked to the Israeli Consumer Price Index (“Index”),
                                            bearing interest at a fixed rate, which:

 

		(a)	has
                                            an average principal time to maturity of at least one month and which is closest to that
                                            of the relevant New Loan as of the date of the New Loan Prepayment Notice (provided
                                            that one bond shall be have an average principal time to maturity that is shorter than that
                                            of the relevant New Loan and the other bond shall have an average principal time to maturity
                                            that is longer than that of the relevant bond), and

 

    -7-

     

    

 

		(b)	has
                                            a total trading volume of at least NIS ten million (10,000,000) per trading day on the last
                                            five trading days prior to the relevant date.

 

If
one or both of the Index linked bonds issued by the State of Israel with the average time to maturity closest to that of the relevant
New Loan do not meet the aforesaid trading volume requirements, then such Index linked, fixed rate, Israeli government bond or bonds,
as the case may be, will be substituted by such bond or bonds which meet the trading volume requirements and which have an average principal
time to maturity closest to that of the relevant New Loan.

 

Numeric
example for calculation of New Loan Prepayment Fee is attached as Exhibit ‎2.8 hereto.

 

For
the avoidance of doubt, any amount repaid on account of the New Loans may not be withdrawn again.

 

		2.9.	Mandatory
                                            Repayment. Without derogating from the provisions of Section 2.11 (Mandatory Repayment)
                                            of the Financing Agreement, and in addition thereto, if the Borrower has not raised equity
                                            capital in an aggregate amount exceeding US$ 5,000,000 by March 31, 2022, then at the request
                                            of Lender in its sole discretion, Borrower shall, on that New Loan Principal Payment Date,
                                            prepay a portion of the New Primary Loan at an amount equal to US$ 500,000, together with
                                            all unpaid New Loan Interest accrued thereon by the actual prepayment date. Such mandatory
                                            prepayment shall not be subject to the New Loan Prepayment Fee.

 

		3.	Closing

 

		3.1.	Time
                                            and Place of Closing. Subject to the terms and conditions contained herein, including
                                            fulfillment of the Disbursement Conditions and the other conditions precedent set out herein
                                            within 45 days following the date hereof, the Lender shall make the New Primary Loan available
                                            to the Company, and the Company shall issue the New Warrant to the Lender, at the closing
                                            (the “New Closing”) which shall take place within one (1) Business Days
                                            of the date on which all closing deliverables set forth in Section ‎4.2 below have been
                                            delivered or, to the extent possible, provision thereof has been waived in writing by Lender
                                            in its sole discretion (the “New Loan Closing Date”).

 

		3.2.	Transactions
                                            at the New Closing. At the New Closing, the Company shall deliver to Lender the following
                                            documents and certificates (unless otherwise waived in writing by the Lender, in its sole
                                            and absolute discretion):

 

		3.2.1.	a
                                            true and correct copy of the resolutions of the Board of Directors of the Company (the “Board”),
                                            in the form attached hereto as Exhibit ‎3.2.1, approving this Amendment
                                            and the transactions contemplated herein and in the ancillary agreements and documents attached
                                            hereto, which shall include:

 

		(a)	the
                                            execution of a floating charge debenture between the Company and the Lender, in the form
                                            attached hereto as Exhibit ‎3.2.1‎(a) (the “New Floating
                                            Charge Debenture”);

 

		(b)	the
                                            execution of a fixed and floating charge debenture between the Company and the Lender, in
                                            the form attached hereto as Exhibit ‎3.2.1‎(b) (the “New
                                            Accounts Pledge Debenture”);

 

    -8-

     

    

 

		(c)	the
                                            execution of a fixed charge debenture between the Company and the Lender, in the form attached
                                            hereto as Exhibit ‎3.2.1‎(c) (the “New IP Pledge Debenture”,
                                            and together with the New Floating Charge Debenture and the New Accounts Pledge Debenture,
                                            the “New Israeli Security Documents”);

 

		(d)	the
                                            execution of a US intellectual property security agreement between the Company and the Lender,
                                            in the form attached hereto as Exhibit ‎3.2.1‎(d) (the “New
                                            IP Security Agreement”, and together with the New Israeli Security Documents, the
                                            “New Company Charge Agreements”);

 

		(e)	the
                                            issuance and delivery at the Closing of a warrant in the form attached hereto as Exhibit
                                            ‎3.2.1‎(e) (the “New Warrant”), in accordance with the
                                            provisions of this Amendment, for no additional consideration, and the approval of the issuance
                                            and delivery of the shares upon the exercise of the New Warrant, all in accordance with the
                                            terms of the Financing Agreement (as amended hereby), and the reservation, at all times,
                                            of a sufficient number of Company shares underlying the New Warrant and issuable upon the
                                            exercise of the New Warrant;

 

		(f)	the
                                            issuance and delivery of the Additional New Warrant subject to and in accordance with the
                                            provisions of the New Warrant, for no additional consideration, and the approval of the issuance
                                            and delivery of the shares upon the exercise of the Additional New Warrant, all in accordance
                                            with the terms of the New Warrant and the Additional New Warrant, and the reservation, at
                                            all times, of a sufficient number of Company shares underlying the Additional New Warrant
                                            and issuable upon the exercise of the Additional New Warrant; and

 

		(g)	the
                                            amendment of the Company’s Articles of Association in order to reflect changes required
                                            pursuant to this Amendment, in the form attached hereto as Exhibit ‎3.2.1‎(f)
                                            (the “Amended and Restated AOA”).

 

		3.2.2.	a
                                            true and correct copy of the duly signed resolutions of the shareholders of the Company,
                                            including resolutions of the required preferred majority shareholders, in the form attached
                                            hereto as Exhibit  ‎3.2.2, approving (i) this Amendment and
                                            the transactions contemplated herein and in the ancillary agreements and documents attached
                                            hereto, (ii) the amendment of the AOA by the Amended and Restated AOA, (iii) the issuance
                                            of the New Warrant to Lender hereunder, and (iv) the issuance of the Additional New Warrant
                                            to Lender in accordance with the provisions of the New Warrant;

 

		3.2.3.	copies
                                            of the Required Consents and Approvals;

 

		3.2.4.	each
                                            of the New Israeli Security Documents duly executed by the Company, together with (i) applicable
                                            10-forms for the registration of the New Israeli Security Documents with the Israeli Companies’
                                            Registrar, (ii) in relation to the New IP Pledge Debenture – applicable registration
                                            form for the registration thereof with the Israeli Patents Office, and (iii) the IIA Approval
                                            (as defined below), in each case of (i) and (ii) above – in forms attached hereto (where
                                            attached) or otherwise reasonably acceptable to Lender, together with an automatic e-mail
                                            confirmation sent by the Companies’ Registrar (and in relation to the New IP Pledge
                                            Debenture – also by the Israeli Patents Office, if applicable) approving receipt of
                                            all New Israeli Security Documents together with the applicable 10-forms sent thereto via
                                            email. If for any reason such automatic confirmation shall not be received reasonably promptly
                                            following submission thereof, then providing Lender with a copy of the e-mails sent to the
                                            Companies’ Registrar and the Israeli Patents Office with all such documents shall satisfy
                                            the above requirement. Within forty five (45) days of the New Closing shall provide Lender
                                            with certificates issued by the Israeli Companies’ Registrar confirming the registration
                                            of all New Israeli Security Documents, and in relation to the New IP Pledge Debenture –
                                            also by the Israeli Patents Office confirming same;

 

    -9-

     

    

 

		3.2.5.	the
                                            New IP Security Agreement duly executed by the Company. Lender shall take care of filing
                                            a UCC-1 statement in respect thereof;

 

		3.2.6.	Copy
                                            of the application made by the Company to the IIA requesting its approval for the creation
                                            of the Liens created under the New Security Documents over all IIA-Funded Know-How (the “IIA
                                            Approval”), in the form agreed with Lender;

 

		3.2.7.	duly
                                            and validly executed New Warrant;

 

		3.2.8.	an
                                            opinion of counsel to the Company, in the form attached hereto as Exhibit ‎3.2.8;
                                            and

 

		3.2.9.	a
                                            Compliance Certificate in the form attached as Exhibit 1.1(b), hereto, duly
                                            executed by the Company’s Chief Executive Officer and/or Chief Financial Officer.

 

		3.2.10.	satisfaction
                                            by Lender that all payments due and payable at New Closing, including payments pursuant to
                                            Section ‎6 below, have been fully paid.

 

		3.3.	Conditions
                                            Precedent. Notwithstanding anything to the contrary contained herein, and in addition
                                            thereto, the Company’s right to receive any New Loan (or any portion thereof), and
                                            the Lender’s obligation to extend any New Loan (or any portion thereof) to the Company,
                                            shall be conditioned on, (i) the absence of a Default on each applicable New Installment
                                            Date and on the date of each Disbursement Request, and (ii) the Company shall have delivered
                                            to Lender all of the documents required to be delivered at the New Closing and in connection
                                            with any installment as set forth herein (as the case may be), all of which shall remain
                                            in full force and effect as of the applicable New Installment Date and the date of the applicable
                                            Disbursement Request.

 

		4.	Securities;
                                            Priority

 

		4.1.	Without
                                            derogating from the Security Documents (as defined in the Financing Agreement), and in addition
                                            thereto, the Company shall further secure the repayment of all Secured Amounts (as such term
                                            is amended hereby) by creating, for the benefit of the Lender, (i) an additional first ranking
                                            and exclusive (together with the Floating Charge Debenture) floating charge (as such term
                                            is defined in the Companies Ordinance [New Version] – 1983) on the Company’s
                                            present and future tangible and intangible assets and rights of any kind, whether contingent
                                            or absolute, including, but not limited to, the Company’s technology and other Intellectual
                                            Property rights as required under the New Floating Charge Debenture, (ii) an additional first
                                            ranking and exclusive (together with the Accounts Pledge Debenture) floating and specific
                                            charge (as such term is defined in the Companies Ordinance [New Version] – 1983) on
                                            the Company’s bank accounts and Cushion Deposit, as required under the New Accounts
                                            Pledge Debenture, and (iii) a first ranking and exclusive (together with the IP Pledge Debenture)
                                            specific charge (as such term is defined in the Companies Ordinance [New Version] –
                                            1983) on the Company’s present and future Intellectual Property rights as required
                                            under the New IP Pledge Debenture.

 

Once
every twelve (12) months, the New IP Pledge Debenture shall be amended to cover any new applications made for registration of patents
by the Group and/or any patents registered thereby during such period (if any), and corresponding UCC-1 filing (together with USPTO filing
in relation to new registered patents) shall be promptly made by the Company, provided that in relation to newly registered patents
the forgoing shall apply within six (6) months of registration thereof, as further provided under Section 7.1.6 of the Financing Agreement.

 

    -10-

     

    

 

		4.2.	The
                                            provisions of Sections 4.2 through 4.6 of the Financing Agreement shall apply hereto as well,
                                            including (without limitation) in relation to the New Secured Amounts (including the New
                                            Loans and New Loan Interest), the New Transaction Agreements (including the New Security
                                            Documents) and etc., mutatis mutandis, to the fullest extent applicable.

 

		5.	Representations
                                            and Warranties of the Company

 

As
an inducement to the Lender to enter into this Amendment and the other New Transaction Agreements and to provide any New Loan, the Company
represents and warrants to the Lender that (a) all of its representations and warranties set out under Section 6 (Representations and
Warranties of the Company) of the Financing Agreement (taking into account the Schedule of Exceptions, as updated and attached as Exhibit
‎5 hereto), and (b) the additional representation and warranties made herein below, are true and correct as of the date hereof,
as of the New Closing Date and, in all material respects, as of each New Installment Date (except as disclosed in writing to Lender and
approved thereby), provided, however, that such materiality qualifier shall not be applicable to any representations and
warranties that already are qualified by materiality in the text thereof and, provided further, that those representations and
warranties expressly referring to a specific date shall be true, accurate and complete as aforesaid as of such date.

 

		5.1.	Authorization

 

		5.1.1.	All
                                            corporate actions on the part of the Company, its officers, directors and shareholders necessary
                                            for the authorization, execution and delivery of this Amendment and the other New Transaction
                                            Agreements, the performance of all obligations of the Company hereunder and thereunder, and
                                            the authorization, issuance (or reservation for issuance), sale and delivery of (a) the New
                                            Warrant and the shares issuable upon the exercise of the New Warrant (the “New Warrant
                                            Shares”), and (b) subject to and in accordance with the provisions of the New Warrant,
                                            the Additional New Warrant and the Additional Warrant Shares (as defined in the New Warrant),
                                            have been taken or will be taken prior to New Closing, and the New Transaction Agreements
                                            constitute and shall constitute at the New Closing valid and legally binding obligations
                                            of the Company, enforceable against it in accordance with their respective terms, except
                                            as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws
                                            of general application affecting enforcement of creditors’ rights generally.

 

		5.1.2.	All
                                            Authorizations required to enable the Company to lawfully conduct its business in the general
                                            nature existing on the date of this Amendment have been obtained or effected and are in full
                                            force and effect and were not breached. Company has not received any notice, warning, or
                                            appeal regarding breach of any of the terms of such Authorizations nor does the engagement
                                            in or execution of the New Transaction Agreements (or any of them) constitute a breach of
                                            any of them.

 

		5.2.	Organizational
                                            Documents. The organizational documents of the Borrower and each Subsidiary and any other
                                            agreement to which it is a party, do not include any restrictions or impediments on the creation
                                            and realization of any portion of the Collateral.

 

		5.3.	Governmental
                                            Consents. No consent, approval, order or authorization of, or registration, qualification,
                                            designation, declaration or filing with, any Governmental Authority on the part of the Company
                                            is required in connection with the consummation of the transactions contemplated by this
                                            Amendment and the other New Transaction Agreements, except for [the filing of the Amended
                                            and Restated AOA with the Companies’ Registrar, the increase of the share capital of
                                            the Company and] the registration of the various charges created under the New Security Documents
                                            with the applicable Governmental Authorities.

 

    -11-

     

    

 

		5.4.	IIA
                                            and Investment Center. Except as provided in Schedule 6.9 of the Schedule of Exceptions,
                                            the transactions contemplated under this Amendment, the New Israeli Security Documents and
                                            any other New Transaction Agreement (including the realization of the Collateral) are not
                                            subject to any right and do not require the approval of the IIA or Investment Center
                                            or the Binational Industrial Research and Development Foundation or any other Governmental
                                            Authority.

 

		5.5.	Compliance
                                            with Other Instruments

 

		5.5.1.	The
                                            execution, delivery and performance of the New Transaction Agreements, and the consummation
                                            of the transactions contemplated hereby and thereby will not (i) result in violation of its
                                            Articles of Association, and to the best knowledge of the Company any judgment, order, lease
                                            or agreement to which it is a party or by which it is bound or any applicable law or other
                                            legal requirement binding on Company, or in an event that results in the creation of any
                                            Lien upon any assets of the Company (except as provided herein) or the suspension, revocation
                                            or non-renewal of any material Authorization applicable to the Company or its business, operations
                                            or assets, or (ii) subject to obtaining the Required Consents and Approvals, require the
                                            consent or approval of any person, which consent or approval has not heretofore been obtained.

 

		5.5.2.	Neither
                                            the execution of any New Transaction Agreement nor the consummation of the transactions contemplated
                                            thereby may result in any Distribution.

 

		5.6.	Collateral.
                                            The Collateral (or any portion thereof) is Free and Clear, other than the security interests
                                            created in favor of the Lender under the Transaction Agreements. The security interests conferred
                                            by the New Security Documents constitute a priority security interest of the type therein
                                            described over the assets and rights referred to therein.

 

		5.7.	Disclosure.
                                            The Company has made available to the Lender all the information reasonably available to
                                            the Company that the Lender has requested for deciding whether to enter into this Amendment
                                            and the other New Transaction Agreements. Neither the New Transaction Agreements, nor any
                                            other statements or certificates made or delivered in connection herewith or therewith contain
                                            any untrue statement of a material fact or omits to state a material fact necessary to make
                                            the statements herein or therein not misleading. There is no material fact or information
                                            relating to the business, prospects, financial condition, affairs, operation or assets of
                                            the Company that was requested by Lender and has not been disclosed to the Lender by the
                                            Company (it being recognized by Lender that the projections and forecasts provided by the
                                            Company in good faith and based upon reasonable assumptions are not viewed as facts and that
                                            actual results during the period or periods covered by such projections and forecasts may
                                            differ from the projected or forecasted results).

 

		6.	Additional
                                            Covenants.

 

		6.1.	Without
                                            derogating from Borrower’s covenants under the Financing Agreement (as amended hereby),
                                            and in addition thereto, Borrower undertakes that the Monthly Gross Bookings Value as of
                                            the end of any calendar month shall be higher than US$ 8.33 million.

 

		6.2.	If
                                            the Company shall not consummate an equity capital raise reflecting the Company a pre-money
                                            valuation of a least US$100,000,000 during the first 6 months following the date hereof,
                                            then, as of the lapse of said 6-month period, the Company shall forthwith issue Lender an
                                            additional warrant (the “Additional New Warrant”) to purchase additional
                                            1,200 Preferred [A] Shares of the Company par value NIS 0.01 each (the “Additional
                                            New Warrant Shares”), in form identical to the New Warrant (mutatis mutandis).
                                            The Company’s covenant to issue the Additional New Warrant in accordance with the above
                                            provisions shall survive termination of this Agreement for any reason whatsoever.

 

    -12-

     

    

 

		7.	Fees
                                            and Expenses

 

		7.1.	Additional
                                            Management Fee. Borrower shall pay Lender annual management fee at the amount reflecting
                                            annual rate of 1% of all New Loan Amounts outstanding at any time under the New Transaction
                                            Agreements (“Additional Management Fee”). Such Additional Management Fee
                                            shall be payable to Lender on monthly basis together with applicable VAT, such that on each
                                            New Loan Interest Payment Date Borrower shall pay Lender Additional Management Fee in respect
                                            of all New Loan Amounts outstanding under the New Transaction Agreements during the New Loan
                                            Interest Period then ended.

 

		7.2.	One
                                            Time Fee. At the earlier of (i) the lapse of 6 months from the New Closing, and (ii)
                                            consummation of the SPAC Merger, Borrower shall pay Lender a one-time fee at the amount of
                                            US$ 200,000 plus VAT (“One Time Fee”), against applicable invoice issued
                                            to the Company.

 

		7.3.	Expenses.
                                            The Borrower shall bear all reasonable costs and expenses incurred by Lender in the negotiation
                                            and consummation of the transactions contemplated hereby, as follows:

 

		7.3.1.	At
                                            the New Closing, all reasonable transaction expenses incurred by Lender in connection with
                                            the negotiation and consummation of the transactions contemplated hereby, including the related
                                            legal fees, shall be paid by Borrower to Lender, by way of deduction from the New Primary
                                            Loan extended at the New Closing and in any event against applicable invoice issued to the
                                            Company, provided that the above payment obligation shall be capped at US$[20,000]
                                            plus VAT. It is clarified that Borrower shall pay all amounts as aforesaid regardless of
                                            whether the New Closing shall have occurred, whereby absent New Closing such payments shall
                                            take place within 10 (ten) Business Days of termination of this Amendment.

 

		7.3.2.	It
                                            is clarified that any additional costs (including legal fees) incurred by the Lender after
                                            the New Closing in relation to amendments or termination to the New Transaction Agreements
                                            (and not relating to the New Closing) or otherwise to ongoing operation of the New Loans
                                            shall be borne by Borrower and paid in accordance with the foregoing provisions, subject
                                            to the bona fide prior agreement by the parties of an appropriate and reasonable cap to such
                                            costs, provided that costs associated with a potential (or actual) Events of Default
                                            and/or costs associated with enforcement of Lender’s rights under the Transaction Agreements
                                            shall not be subject to any such prior agreement.

 

		7.3.3.	All
                                            costs relating to the registration and removal of Liens created pursuant to the terms of
                                            the Transaction Agreements and to the realization thereof shall be borne by the Company.
                                            Without derogating from the foregoing, the Company shall be responsible to the cost of the
                                            registration of the relevant Liens outside of Israel in accordance with the provisions hereof
                                            (in addition to the above cap).

 

		7.4.	Agreed
                                            Compensation. If the New Closing shall not take place for any reason whatsoever (other
                                            than any reason related solely to Lender), Lender shall be entitled to agreed compensation
                                            at the amount of NIS 100,000, which shall be paid thereto in addition all expenses owed to
                                            Lender in accordance with the foregoing provisions.

 

    -13-

     

    

 

		8.	VAT.
                                            Unless specifically set forth otherwise, all amounts under this Amendment are exclusive of
                                            any VAT. VAT shall be added according to applicable law to all payments of New Loan Interest
                                            due hereunder to Lender and all other Due Payments (as such term is amended hereby) and any
                                            other amounts payable hereunder or in connection herewith to Lender, to be paid against and
                                            subject to a duly issued invoice to be issued by Lender.

 

		9.	Other
                                            Provisions.

 

All
other terms and provisions of the Financing Agreement, including (without limitation), the provisions of Section 2.7 (Step-Up Interest;
Arrears Interest); Section 2.9 (Payments); Section 2.12 (Termination); Section 5 (Acceleration) in its entirety (including the powers
of attorney granted to Lender therein); Section 7 (Undertakings of the Borrower) in its entirety; Section 8 (Covenants) in its entirety
(provided that Borrower’s undertaking to Make the Cushion Deposit Whole in accordance with the provisions of Section 8.1 of the
Financing Agreement shall take into account the New Loan Basic Cushion Deposit Amount and the New Loan Additional Cushion Deposit Amount)
and Sections 10 through 13 (Indemnity; Illegality; Set-off and Lien and Miscellaneous) in their entirety, and all obligations and undertakings
of Borrower under or in connection with any of the foregoing (other than such obligation and undertakings that were due to be fulfilled
by a certain date prior to the date hereof and had already been so fulfilled), shall apply hereto as well, including (without limitation)
in relation to the New Secured Amounts (including the New Loans and New Loan Interest), the New Transaction Agreements (including the
New Security Documents) and etc., mutatis mutandis, to the fullest extent applicable.

 

[Remainder
of the Page Intentionally left Blank]

 

    -14-

     

    

 

IN
WITNESS WHEREOF the parties have signed this Amendment in one or more counterparts as of the date first appearing above.

 

	 	 
	Holisto Ltd.
	 
	By:	 	 
	Title:	 	 
	 	 	 
	 	 
	Discount Capital Ltd
	 
	By:	 	 
	Title:	 	 

 

Acknowledged
and agreed to by the following entities with respect to the provisions applicable to it (if any):

 

	 	 
	Splitty Travel Inc.
	 
	By:	 	 
	Title:	 	 

 

	 	 
	Splitty Travel UK Ltd.
	 
	By:	 	 
	Title:	 	 

 

[Signature
Page to Amendment No. 1 to Financing Agreement]

 

 

-15-Exhibit
10.24

 

Date: September [__], 2021

 

		To:	Discount
                                            Capital Ltd.

 

WARRANT

 

To
purchase Shares of

 

Holisto
Ltd. (the “Company”)

 

at
a per share price and subject to the terms detailed below

 

THIS
IS TO CERTIFY THAT, Discount Capital Ltd. (the “Holder”) is entitled to purchase Warrant Shares from the
Company, at any time and from time to time, during the Warrant Period, at the Exercise Price per each Warrant Share, all in accordance
with the terms and conditions set forth herein.

 

This
Warrant (this “Warrant”) is issued to the Holder in connection with Amendment no. 1 (the “Amendment”)
to that certain Financing Agreement dated March 25, 2021 by and between the Company and the Holder (as amended by the Amendment and as
may be further amended from time to time, the “Financing Agreement”), and is in addition to the Warrant (as defined
in the Financing Agreement) issued to Holder pursuant to the Financing Agreement originally executed (the “Existing Warrant”).

 

1.
Class and Number of Warrant Shares.

 

1.1.
This Warrant is exercisable into 2,400 Preferred A Shares of the Company par value NIS 0.01 each (the “Warrant
Shares”). The Warrant Shares shall have all rights, preferences and privileges that are attached to the shares of the same
class of the Warrant Shares and such other rights, preferences and privileges that are granted or will be granted to the holders
thereof.

 

1.2. Without derogating
from Section ‎1.1, and in addition thereto, if the Company shall
not consummate equity capital raise reflecting the Company a pre-money valuation of a least US$ 100,000,000 during the first 6 months
following the date hereof, then, as of the lapse of said 6-month period, Holder shall be entitled to be issued additional 1,200 Preferred
A Shares of the Company par value NIS 0.01 each (the “Additional Warrant Shares”) on the same terms provided for herein,
and for that purpose the Company shall forthwith issue Holder an additional warrant for the issuance of the Additional Warrant Shares,
in form identical to this Warrant (mutatis mutandis) but excluding this Section ‎1.2
(the “Additional New Warrant”), exercisable by Holder during the Warrant Period.

 

2.
Exercise Price.

 

The
exercise price for each Warrant Share (the “Exercise Price”) purchasable hereunder shall be the par value of each
Warrant Share (i.e., NIS 0.01 as of the date hereof).

 

3.
Warrant Period.

 

3.1. This
Warrant may be exercised, in whole or in part, commencing on the date hereof (the “Commencement Date”) and until the
earlier of (i) Target Date, and (ii) the consummation of a Qualified Acquisition (the “Warrant Period”). It is clarified
that this Warrant is independent and shall survive termination of the Financing Agreement (including termination of the Amendment) for
any reason whatsoever.

 

3.2. To
the extent that this Warrant was not exercised prior to the last Business Day of the end of the Warrant Period, then, unless otherwise
notified by the Holder to the Company, this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to
the provisions hereof as to all Warrant Shares for which it shall not previously have been exercised, and the Company shall promptly
notify Holder of the number of Warrant Shares issued upon such exercise to Holder; provided, however, that if the Warrant
is automatically exercised in connection with a Qualified Acquisition, such exercise and the expiry of the Warrant shall be conditioned
upon the terms set forth below.

 

     

     

    

  

3.3.
For purposes herein:

 

“Acquisition”
means any transaction or series of related transactions involving: (i) the sale, lease, or grant of an exclusive perpetual, worldwide
license, or other disposition of all or substantially all of the assets of the Company, provided that all or substantially all of the
consideration for such transaction and which are available for distribution in accordance with applicable law and obligations of the
Company is proposed to be distributed, as soon as legally practicable thereafter and in any event within 120 days from the consummation
thereof, to the shareholders of the Company; (ii) any merger or consolidation of the Company into or with another person or entity (other
than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in
which the shareholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own
less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after
such merger, consolidation or reorganization (or, if such Company shareholders beneficially own a majority of the outstanding voting
power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor
entity is not the Company); or (iii) any sale or other transfer by the shareholders of the Company of all or substantially all of the
shares of the Company.

 

“IPO”
shall mean public offering and sale of its ordinary shares pursuant to an effective registration statement under the Act or any other
relevant securities laws.

 

“Marketable
Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting
requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended or similar laws of any other relevant
jurisdiction, and is then current in its filing of all required reports and other information under relevant securities laws; (ii) the
class and series of shares or other security of the issuer that would be received by Holder in connection with the Qualified Acquisition
were Holder to exercise this Warrant on or prior to the closing thereof is then traded on a nationally recognized securities exchange,
inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Qualified Acquisition, Holder would
not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder
in such Qualified Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Qualified Acquisition,
except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y)
does not extend beyond six (6) months from the closing of such Qualified Acquisition.

 

“Qualified
Acquisition” means an Acquisition (a) in which the consideration to be received by the Holder shall consist solely of cash,
Marketable Securities or a combination of cash and Marketable Securities or (b) that triggers the Liquidation Preference provisions of
the Company’s Articles of Association. Notwithstanding the provisions hereof, it is hereby agreed that the SPAC Merger (as defined
in the Amendment) shall be considered a Qualified Acquisition for the purposes hereof, but shall not be considered a Qualified Acquisition
for purposes of the Existing Warrant.

 

    2

     

    

  

3.4. “Target
Date” means 5:00pm Israel time on the seventh (7th) anniversary of the Commencement Date. Upon the closing of a
Qualified Acquisition, unless otherwise notified by the Holder to the Company, this Warrant shall automatically be deemed on and as of
such date to be exercised pursuant to Section ‎3.2 above as to all Warrant Shares for which it shall not previously have been exercised,
and the Company shall promptly notify Holder of the number of Warrant Shares issued upon such exercise to Holder. Upon the closing of
an Acquisition (other than a Qualified Acquisition), the acquiring, surviving or successor entity shall assume this Warrant and the obligations
of the Company hereunder, and this Warrant shall, from and after such closing, be exercisable for the same class, number and kind of
securities, cash and other property as would have been paid for or in respect of the Shares issuable (as of immediately prior to such
closing) upon exercise in full hereof as if such Shares had been issued and outstanding on and as of such closing, at an aggregate Exercise
Price equal to the aggregate Exercise Price in effect as of immediately prior to such closing; and subject to further adjustment thereafter
from time to time in accordance with the provisions of this Warrant.

 

3.5. The
Company shall provide the Holder with written notice of any Acquisition simultaneously with the notice of the same to the Company’s
shareholders (in their capacity as such) but in any event at least ten (10) Business Days prior the consummation of the Acquisition,
which notice shall detail the material terms of such Acquisition (the “Acquisition Notice”). Thereafter, the Company
shall provide the Holder with written updates regarding the negotiations and the terms of the proposed Acquisition on a basis of the
updates provided to the Company’s shareholders and shall provide the Holder with the final version of the definitive agreements
simultaneously when provided to its shareholders.

 

3.6. If
the Holder provided an Exercise Notice (as defined below) which is contingent upon the consummation of an Acquisition and (i) the closing
of such Acquisition shall not occur within 120 days following the delivery of the Exercise Notice, or (ii) the final material terms based
on which the Acquisition is consummated are adverse than those set forth in the Acquisition Notice, then the Holder, at its sole discretion,
may withdraw the Exercise Notice by written notice to the Company, whereupon the Exercise Notice shall be null and void, ipso facto,
and Holder’s rights hereunder shall remain in full force an effect as if such Exercise Notice has not been provided thereby (the
foregoing without derogating from the termination provisions of this Warrant).

 

4.
Exercise for Cash.

 

4.1. Holder
may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company an executed copy of this
Warrant, accompanied by a written notice of exercise in the form attached hereto as Exhibit A (“Exercise Notice”)
and payment therefor as set forth below. In no event shall an original ink-signed paper copy of this Warrant be required for any exercise
of a Holder’s rights hereunder, nor shall this Warrant or any physical copy thereof be required to be physically surrendered at
the time of any exercise hereof.

 

4.2. Payment
of the Exercise Price to the Company for the number of Warrant Shares specified in such notice shall be made concurrently with the submission
of the Exercise Notice in immediately available funds, in U.S. Dollars (to an account designated by the Company), a check, or other form
of payment acceptable to the Company for the aggregate Exercise Price for the Shares being purchased.

 

    3

     

    

 

5.
Deleted.

 

6.
Issuance of the Warrant Shares.

 

6.1. Upon
delivery of the Exercise Notice, or upon automatic exercise pursuant to Section ‎3.2 above, the Company shall issue promptly to the
Holder the Warrant Shares to which the Holder is entitled thereto.

 

6.2. Upon
receipt by the Company of the Exercise Notice, or upon automatic exercise pursuant to Section ‎3.2 above, the Holder shall be deemed
to be the Holder of the Warrant Shares issuable upon such exercise, notwithstanding that the share transfer books of the Company shall
then be closed and that certificates representing such Warrant Shares shall not then be actually delivered to the Holder. No fractions
of shares shall be issued in connection with the exercise of this Warrant and the number of Warrant Shares shall be rounded to the nearest
whole number.

 

6.3. In
the event of exercise of a portion of this Warrant, the Company shall concurrently issue to the Holder a replacement Warrant on the same
terms and conditions as this Warrant, but representing the number of Warrant Shares remaining after such partial exercise.

 

6.4. The
Company (subject to the provisions of Section 25 below) shall pay all duties, commission, taxes and other charges applicable to it, that
may be payable in connection with the issuance of the Warrant Shares and the preparation and delivery of share certificates pursuant
to this Section ‎6 in the name of the Holder.

 

7.
Reservation of Shares; Preservation of Rights of Holder.

 

7.1. The
Company hereby agrees and undertakes that during the Warrant Period it will maintain and reserve, free from preemptive or other participation
rights, such number of authorized but un-issued Warrant Shares so that this Warrant may be exercised in accordance with its terms.

 

7.2. The
Company further agrees and undertakes that it will not, by amendment of its organizational documents or through reorganization, recapitalization,
voluntary liquidation, consolidation, merger, dissolution, winding up or sale of assets, or by any other voluntary act (collectively,
“Non Performance Events”), avoid or seek to avoid the observance or performance of any of the covenants, stipulations
or conditions to be observed or performed hereunder by the Company, or impair the economic interest of the Holder in connection herewith,
but will at all times in good faith assist in carrying out all of the provisions hereof and in taking of all such actions and making
all such adjustments as may be necessary or appropriate in order to fulfill the provisions hereof.

 

    4

     

    

 

8.
Representations and Covenants of the Company.

 

Without
derogating from any representation or covenant set forth in the Financing Agreement, the Company hereby represents and covenants to the
Holder as follows:

 

8.1. The
number of Warrant Shares first set forth above represent not less than 0.44% of the Company’s total issued share capital, calculated
on and as of the date of issuance hereof on a fully-diluted, ordinary share-equivalent basis assuming (i) the conversion into ordinary
shares of all outstanding securities and instruments (including, without limitation, securities deemed to be outstanding pursuant to
clause (ii) of this Section ‎8.1) convertible by their terms into ordinary shares (regardless of whether such securities or instruments
are by their terms now so convertible), (ii) the exercise in full of all outstanding options, warrants (including, without limitation,
this Warrant) and other rights to purchase or acquire ordinary shares or securities exercisable for or convertible into ordinary shares
(regardless of whether such options, warrants or other rights to purchase or acquire are by their terms now exercisable); and (iii) the
inclusion of all ordinary shares reserved for issuance under all of the Company’s incentive share and share option plans and not
now subject to outstanding grants or options, but specifically excluding outstanding SAFEs for an aggregate amount of US$2,000,000
which are outstanding as of the date of issuance hereof. The Company’s capitalization table attached hereto as Exhibit B
is true and complete as of the date of issuance hereof.

 

8.2. This
Warrant has been duly authorized by all corporate action on part of the Company and executed by the Company and is a valid and binding
obligation of the Company enforceable in accordance with its terms, except (in relation to such enforceability) (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to
or affecting the enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies.

 

8.3. The
Warrant Shares are or will be immediately prior to their issuance duly authorized and reserved for issuance by the Company, and the Warrant
and the Warrant Shares when issued in accordance with the terms hereof, will be validly issued, fully paid (upon payment of the aggregate
Exercise Price thereof in full) and non-assessable, free and clear from any third party rights (other than restriction on transfer provided
for herein or under the Company’s Articles of Association (as amended from time to time) or under applicable securities laws) and
the issuance of this Warrant and the Warrant Shares will not (and the Company undertakes to ensure it will not) be subject to any preemptive
rights (or other similar rights) and/or any other third-party rights and will not trigger any anti-dilution protection or similar rights.

 

8.4. The
execution and delivery of this Warrant is not, and the issuance of the Warrant Shares upon exercise of this Warrant in accordance with
the terms hereof will not be, inconsistent with the Articles of Association of the Company as in effect at the date of issuance hereof,
do not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, do not conflict with or contravene
any provision of, or constitute default under, any indenture, mortgage, contract or other instrument to which the Company is a party
or by which it is bound or, require the consent, approval of, the giving of notice to, the registration with or the taking of any action
in respect of or by, any federal, state or local government authority or agency or any other person.

 

8.5. The
most senior voting class of shares of the Company issued as of the date hereof are the Series A-2 Preferred Shares, nominal value NIS
0.01 each, Series A-1 Preferred Shares, nominal value NIS 0.01 each, and Series A Preferred Shares, nominal value NIS 0.01 each, which
were issued initially on March 19, 2019, at a price per share of US$ 27.129, US$ 29.795 and US$ 36.9090, respectively.

 

8.6. Except
as provided under Exhibit C hereto, (a) there are no other preemptive rights, rights of first refusal, convertible securities,
outstanding warrants, options or other rights to subscribe for, purchase or acquire from the Company any share capital of the Company
and there are no contracts or binding commitments providing for the issuance of, or the granting by the Company of rights to acquire,
any share capital of the Company or under which the Company is, or may become, obligated to issue any of its securities, and (b) the
Company has not granted or agreed to grant any registration rights, including piggyback rights, to any person or entity.

 

    5

     

    

 

 9. Representations and Warranties of the Holder.

 

The
Holder represents and warrants to the Company as follows:

 

9.1. This
Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired for investment for Holder’s
account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Securities Act
of 1933, as amended (The “Act”). Holder also represents that it has not been formed for the specific purpose of acquiring
this Warrant or the Warrant Shares.

 

9.2. Holder
is aware of the Company’s business affairs and financial condition and, to the best of its knowledge, has received or has had full
access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the optional
acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers
from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary
to verify any information furnished to Holder or to which Holder has access.

 

9.3. Holder
understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder can bear the economic risk
of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or
business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities.

 

9.4. Holder
is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

 

9.5. Holder
understands that this Warrant and the Warrant Shares issuable upon exercise hereof have not been registered under the Act in reliance
upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment
intent as expressed herein. Holder understands that this Warrant and the Warrant Shares issued upon any exercise hereof must be held
indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from
such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act.

 

 10. Exchange or Loss of Warrant.

 

Without
derogating form the provisions of Section ‎4.1:

 

10.1. 
Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant,
and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and deliver, in lieu of this Warrant, a new
Warrant of like tenor and date; and

 

10.2. If
at any time this Warrant is rejected by any person (including but not limited to, paying or escrow agents) or any such person fails to
comply with the terms of this Warrant based on this Warrant being presented to such person as an electronic record, a printout thereof,
or any signature hereto being in electronic form, the Company, shall, promptly upon Holder’s request without indemnity, execute
and deliver to Holder, in lieu of electronic original versions of this Warrant, a new warrant of like tenor and amount in paper form
with original ink signatures.

 

    6

     

    

 

11. Adjustment.

 

The
number and kind of securities purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the
occurrence of certain events, provided that in no event shall the aggregate Exercise Price paid by the Holder in respect of all
securities underlying the Warrant be increased:

 

11.1. Adjustment
for Shares Subdivisions and Combinations. If the Company at any time or from time to time, during the term of this Warrant, effects
a subdivision of its outstanding shares, the number of Warrant Shares issuable upon exercise of this Warrant immediately before the subdivision
shall be proportionately increased. Conversely, if the Company at any time or from time to time, during the term of this Warrant, combines
its outstanding shares, the number of Warrant Shares issuable upon exercise of this Warrant immediately before the combination shall
be proportionately decreased. In each such case, the Exercise Price shall be proportionately increased or decreased, as applicable. Any
adjustment under this Section ‎11.1 shall become effective at the close of business on the date on which the subdivision or combination
becomes effective.

 

11.2. Adjustments
for Dividends and Distributions. In the event that the Company at any time or from time to time declares, or fixes a record date
for the determination of holders of shares of the Company entitled to receive, a dividend or other distribution payable in securities
or other property (other than cash) of the Company, then in each such event, provision shall be made so that the Holder shall receive
upon exercise of this Warrant, in addition to the number of Warrant Shares receivable thereupon, the number of securities or a portion
of such other property of the Company that the Holder would have received had this Warrant been exercised for Warrant Shares immediately
prior to such event (or the record date for such event, as the case may be) and had the Holder thereafter, during the period from the
date of such event to and including the date of exercise, retained such securities receivable by it as aforesaid during such period,
subject to all other adjustments called for during such period under this Section ‎11.

 

11.3. Deleted.

 

11.4. Adjustment
for Recapitalization, Reclassification, Exchange and Substitution. If the Warrant Shares issuable hereunder are changed into the
same or a different number of shares of any class or classes of shares, whether by recapitalization, reclassification or otherwise (other
than a subdivision or combination of shares or shares dividend or a reorganization, merger, consolidation or sale of assets, provided
for elsewhere in this Section ‎11), then in any such event the Holder shall have the right thereafter to exercise this Warrant into
the kind and amount of shares and other securities receivable upon such recapitalization, reclassification or other change, by holders
of the number of shares of the same class of the Warrant Shares for which this Warrant might have been exercised immediately prior to
such recapitalization, reclassification or change, all subject to further adjustment as provided herein. The provisions of this Section
‎11.4 shall similarly apply to successive reclassifications, exchanges, combinations, substitutions, replacements or other similar
events.

 

11.5. Reorganization,
Mergers, Consolidations or Sales of Assets. Without derogating from any other provision contained herein, if at any time or from
time to time, during the term of this Warrant, there is a capital reorganization of the shares of the Company (other than a subdivision,
combination, recapitalization, reclassification or exchange of shares provided for elsewhere in this Section ‎11) or a merger or
consolidation of the Company with or into another corporation, in each case, which is not an Acquisition, then, as a part of such reorganization,
merger or consolidation, provision shall be made so that the Holder shall thereafter be entitled to receive upon exercise of this Warrant
the number of shares or other securities or property of the Company, or of the successor corporation resulting from such merger or consolidation,
to which a holder of Warrant Shares deliverable upon exercise hereof would have been entitled upon such capital reorganization, merger
or consolidation. In any such case, appropriate adjustment shall be made in the application of the provisions of this Warrant and the
Company’s Articles of Association (or the organizational documents of any successor corporation) with respect to the rights of
the Holder after the reorganization, merger or consolidation to the end that the provisions of this Warrant and the Company’s Articles
of Association (or the organizational documents of any successor corporation) (including adjustment of the number of shares issuable
upon exercise of this Warrant) shall be applicable after that event and be as nearly equivalent to the provisions hereof as may be practicable.

 

    7

     

    

 

11.6. Conversion
of Preferred Shares. If the class of the Warrant Shares (the “Class”) is a class and series of the Company’s
convertible preferred shares, in the event that all outstanding shares of the Class are converted, automatically or by action of the
holders thereof, into ordinary shares pursuant to the provisions of the Company’s Articles of Association (as amended and in effect
from time to time), including, without limitation, in connection with the Company’s initial, underwritten public offering and sale
of its ordinary shares pursuant to an IPO, then from and after the date on which all outstanding shares of the Class have been so converted,
this Warrant shall be exercisable for such number of ordinary shares into which the Shares would have been converted had the Shares been
outstanding on the date of such conversion, and the Exercise Price shall equal the Exercise Price in effect as of immediately prior to
such conversion divided by the number of ordinary shares into which one Share would have been converted, all subject to further adjustment
thereafter from time to time in accordance with the provisions of this Warrant.

 

11.7. Limited
Anti-Dilution Protection. The Holder shall be entitled to the same anti-dilution protection set forth in the Company’s Articles
of Association as in effect from time to time in respect of shares of the same class of the Warrant Shares, such that upon the occurrence
of a Dilutive Issuance (as such terms are defined in the Company’s Articles of Association), the applicable conversion price of each
Warrant Share (if and when issued) shall be reduced in accordance with the terms and provisions set forth in the Company’s Articles
of Association as if such Warrant Shares were issued and outstanding at the date of such Dilutive Issuance.

 

11.8. Other
Transactions. In the event that the Company shall issue shares to its shareholders as a result of a split-off, spin-off or the like,
then the Company shall only complete such issuance or other action if, as part thereof, allowance is made to protect the economic interest
of the Holder either by increasing the number of Warrant Shares or by procuring that the Holder shall be entitled, on economically proportionate
terms, to acquire additional shares of the spin-off or split-off entities.

 

11.9. Notice
of Capital Changes and Transfer of Shares. If the Company performs any of the actions or enters into any of the transactions described
in this Section ‎11 or in the event that the Company receives a notice by a shareholder pursuant to which a transfer of shares which
may trigger Co-Sale rights pursuant to the Company’s Articles of Association is contemplated (including notice of any Offer, as
define in the Company’s Articles of Association), then, in any one or more of the said cases, the Company shall, at its expense,
provide the Holder prior written notice of such actions and/or transactions, including a description thereof and any record date relevant
to such actions and transactions. Such written notice shall be provided at least ten (10) Business Days prior to the action and/or transaction
in question or the date to provide notice of exercise in respect of any such action and/or transaction (whichever is earlier) provided
that the Company shall forward Holder any Offer it receives within one (1) Business Days of receipt thereof.

 

    8

     

    

 

11.10. Notice
of Certain Events. If the Company proposes at any time to:

 

 (a) declare any dividend or distribution upon the outstanding shares of the Class or of ordinary shares, whether in cash, property, shares, or other securities and whether or not a regular cash dividend;

 

 (b) offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s shares (other than pursuant to contractual pre-emptive rights);

 

 (c) effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Class;

 

 (d) effect an Acquisition or to liquidate, dissolve or wind up;

 

 (e) effect an IPO; or

 

 (f) any other actions or transaction described in this Section ‎11 or in the event that the Company receives a notice by a shareholder pursuant to which a transfer of shares which may trigger Co-Sale rights pursuant to the Company’s Articles of Association is contemplated (including notice of any Offer),

 

then,
in connection with each such event, the Company shall give Holder:

 

		(1)	in
                                            the case of the matters referred to in (a) and (b) above, at least seven (7) Business Days
                                            prior written notice of the earlier to occur of the effective date thereof or the date on
                                            which a record will be taken for such dividend, distribution, or subscription rights (and
                                            specifying the date on which the holders of outstanding shares of the Class will be entitled
                                            thereto) or for determining rights to vote, if any;

 

		(2)	in
                                            the case of the matters referred to in (c) and (d) above at least seven (7) Business Days
                                            prior written notice of the date when the same will take place (and specifying the date on
                                            which the holders of outstanding shares of the Class will be entitled to exchange their shares
                                            for the securities or other property deliverable upon the occurrence of such event and such
                                            reasonable information as Holder may reasonably require regarding the treatment of this Warrant
                                            in connection with such event giving rise to the notice);

 

		(3)	with
                                            respect to the IPO (including the SPAC Merger), at least ten (10) Business
Days prior written notice of the date on which the Company proposes to file its registration statement in connection therewith (or the
equivalent statements in case of the SPAC Merger); and

 

		(4)	in
                                            the case of the matters referred to in (f) above, at least seven (7) Business Days prior
                                            written notice of the date on which the Company proposes to take the relevant action or enter
                                            the relevant transaction (or upon receiving a notice by a shareholder pursuant to regarding
                                            a transfer of shares which may trigger Co-Sale rights), provided that the Company shall forward
                                            Holder any Offer it receives within one (1) Business Days of receipt thereof.

 

    9

     

    

 

The
Company will also provide information requested by Holder from time to time, within a reasonable time following each such request, that
is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements. Prior to the IPO or the
SPAC Merger, such information may include, but shall not be limited to, the Company’s then-current summary capitalization table,
the price per share for which the Company most recently prior thereto sold or issued shares of its convertible preferred stock to investors
for cash in a bona fide equity financing of the Company, and, if exists at such time, the Company’s most recent completed valuation,
approved by the Company’s Board of Directors, of a share of the same class as the Warrant Shares for purposes of the Company’s
compliance with Section 409A of the Internal Revenue Code of 1986, as amended (or the corresponding section of any successor statute)
(if applicable). Holder agrees to treat and hold all information provided by the Company pursuant to this Warrant in confidence in accordance
with the provisions of Section 13.3 of the Financing Agreement (regardless of whether the Financing Agreement shall then be in effect).

 

11.11. Notice
of Adjustments and Related Provisions. Whenever the number or type of Warrant Shares purchasable hereunder or the Exercise Price
shall be adjusted pursuant to Section ‎11 hereof, the Company shall, at its expense, prepare a certificate signed by the chief financial
officer of the Company setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method
by which such adjustment was calculated, the Exercise Price and the number of Warrant Shares and other assets purchasable hereunder after
giving effect to such adjustment, and shall provide such certificate to the Holder. Furthermore, throughout the term of this Warrant,
the Company shall, concurrently with and as a condition to, any distribution which triggers any of the adjustments set forth above, set
aside such portion of the distribution to be delivered to the Holder upon exercise of this Warrant.

  

 12. Information Rights.

 

12.1. The
Company shall provide the Holder with annual and quarterly financial statements and such other information as and when provided to Major
Holders (regardless of whether or not the Holder qualifies as a Major Holder), as defined in and pursuant to the terms of that certain
Shareholders’ Rights Agreement dated March 19, 2019, by and among the Company, the Investors and the Key Holders parties thereto
(as amended and restated from time to time the “IRA”) and such other information provided to all of its shareholders
or as may be reasonably requested by the Holder.

 

12.2. Section
‎12.1 above shall survive the exercise of this Warrant, such that, following the exercise of the Warrant, the Holder, for as long
as it is a shareholder of the Company, shall be entitled to receive from the Company the information set forth in Section ‎12.1 above.

 

12.3. Upon
the first exercise of the Warrant, the Holder shall join the IRA as a “Preferred Holder” (to the extent not previously joined
same) and the Company has taken or will take upon the exercise of the Warrant all necessary actions (corporate or otherwise) required
to effect such joinder, in accordance with the terms of the IRA.

 

12.4. The
Company’s obligation under Section ‎12.1 above shall terminate and shall be of no further force or effect upon the earliest
to occur of (i) the closing of the Company’s initial public offering of its Ordinary Shares pursuant to an effective registration
statement under the United States Securities Act of 1933, as amended, or under other similar law of other jurisdiction, (ii) the date
on which the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Securities Act or
the Securities Exchange Act of 1934, or (iii) consummation of a Liquidation Event, as such term is defined in the Company’s Articles
of Association, pursuant to which the Holder ceases to be a Holder or a shareholder.

 

    10

     

    

 

 13. Assignment.

 

The
Company may not assign its obligations under this Warrant to any other entity without the written consent to the Holder. This Warrant
and all of Holder’s rights hereunder may be transferred by Holder, in all or in part, to any person or entity, subject only to
the approval of the Board of Directors of the Company (not to be unreasonably withheld). Upon any permitted transfer, the Company will
issue and deliver to each of the Holder and the transferee new certificates evidencing the Warrant (or any portion thereof).

 

Any
transfer of the Warrant Shares following the exercise of the Warrant, shall be subject to the transfer restrictions set forth in the
Company’s Articles of Association then in effect, and the term Permitted Transferee in respect of the Holder shall be as set forth
in the Company’s Articles of Association then in effect.

 

 14. Rights of the Holder.

 

Other
than as expressly set forth herein, prior to the exercise of this Warrant and issuance of the Warrant Shares (or the date on which the
Holder is deemed to be the Holder of the Warrant Shares pursuant to Section ‎6.2 above), the Holder shall not, by virtue hereof,
be entitled to any rights of a shareholder in the Company.

 

 15. Attorneys’ Fees.

 

In
the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute
shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

 

 16. Publicity.

 

Other
than in the framework of any due diligence and/or in connection with consultation with its advisors, provided that any recipient of such
information will execute a standard confidentiality undertaking, or as required by applicable law, the Company and the Holder will keep
this Warrant and the terms set forth herein in confidence.

 

 17. Further Assurances.

 

The
Company shall perform such further acts and execute such further documents as may be necessary to carry out and give full effect to the
provisions of this Warrant and the intentions of the parties as reflected hereby.

 

 18. Titles and Subtitles.

 

The
titles and subtitles used in this Warrant are used for convenience only and are not to be considered in construing or interpreting this
Warrant.

 

    11

     

    

 

 19. Notices.

 

All
notices and other communications given or made pursuant to this Warrant shall be in writing and shall be deemed effectively given upon
the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail during
normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day
in Tel Aviv, or (c) one (1) business day following deposit with a nationally/internationally recognized overnight courier, freight prepaid
specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties
at their address as set forth below or to such e-mail address, or address as subsequently modified by written notice given in accordance
with this Section ‎19:

 

	 	if to the Company:
	 	 	 
	 		Holisto Ltd.
	 	 	Address: 2 Sde Nim Rishon Lezion,
    Israel
	 	 	Attention: Eran Shust
	 	 	E-mail: eran@splittytravel.com
	 	 	 
	 	with a copy to
    (which shall not constitute a notice):
	 	 
	 		Shibolet & Co.
	 	 	Museum Tower, Berkowitz St 4,
    Tel Aviv-Yafo
	 	 	Attention: Ofer Ben Yehuda, Maya
    Koubi Bara-nes
	 	 	Email: Error! Hyperlink reference
    not valid.
	 	 	Error! Hyperlink
    reference not valid.
	 	 	 
	 	if to the Holder:
	 	 	 
	 	 	Discount Capital Ltd.
	 	 	22 Rothschild Blvd, Tel Aviv,
    Isarel
	 	 	Attn: Ido Avron,
    Yifat Samet-Shalit
	 	 	Email: idoa@dcapital.co.il
	 	 	yifat@dcapital.co.il
	 	 	 
	 	with a copy to (which
    shall not constitute a notice):
	 	 	 
	 		Meitar | Law Offices
	 	 	16 Abba Hillel Rd. Ramat-Gan
    5250608, Israel
	 	 	Fax: +972-3-6103111
	 	 	Attn: Assaf Oz, Eli Wieder
	 	 	Email: aoz@meitar.com
	 	 	   Error!
    Hyperlink reference not valid.

 

 20. Severability; Survival.

 

If
any provision of this Warrant is determined to be invalid, illegal or unenforceable, the invalidity or unenforceability of any provision
hereof shall in no way affect the validity or enforceability of any other provision. In the event of any such determination, then, the
parties agree to negotiate in good faith to modify this Warrant to fulfill as closely as possible the original intents and purposes hereof.
Termination or expiration of this Warrant shall not, however, relieve or release the Company or the Holder from obligations which by
their nature should survive the termination or expiration thereof (including, without limitation, the provisions of Sections ‎8,
9, ‎12 and ‎16).

 

    12

     

    

 

 21. Delays or Omissions.

 

No
delay or omission to exercise any right, power or remedy accruing to any party under this Warrant, upon any breach or default of under
this Warrant, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to
be a waiver of any such breach or default, or an acquiescence therein, or of any similar breach or default thereafter occurring; nor
shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.

 

 22. Amendments and Waivers.

 

Any
term of this Warrant may be amended (either generally or in a particular instance and either retroactively or prospectively), only with
the written consent of the Company and the Holder. The observance of any term of this Warrant may be waived (either generally or in a
particular instance and either retroactively or prospectively) only by the written waiver of the party so waiving its right.

 

 23. Counterparts; Electronic Signatures; Status as Certificated Security. 

 

This
Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement.  Company, Holder and
any other party hereto may execute this Warrant by electronic means and each party hereto recognizes and accepts the use of electronic
signatures and records by any other party hereto in connection with the execution and storage hereof.  To the extent that this Warrant
or any agreement subject to the terms hereof or any amendment hereto is executed, recorded or delivered electronically, it shall be binding
to the same extent as though it had been executed on paper with an original ink signature.  The fact that this Warrant is executed,
signed, stored or delivered electronically shall not prevent the transfer by any Holder of this Warrant pursuant to Section ‎13 or
the enforcement of the terms hereof. Physical possession of the original of this Warrant or any paper copy thereof shall confer
no special status to the bearer thereof.

 

 24. Governing Law; Jurisdiction.

 

This
Warrant shall be governed by and construed in accordance with the laws of the State of Israel without giving effect to its conflict of
laws or rules. Any dispute arising under or in relation to this Warrant shall be resolved exclusively in the competent court in Tel Aviv-Jaffa
and each of the parties hereby submits irrevocably to the exclusive jurisdiction of such court.

 

 25. Tax.

 

25.1. Holder
shall bear full responsibility for all tax obligations and consequences relating to the transfer or exercise of this Warrant or sale
of the Warrant Shares issuable upon the exercise of this Warrant, which by their nature apply to holders of warrants. In the event that
the Company is required under applicable law to withhold any tax as a result of the exercise of this Warrant and/or the issuance of the
Warrant Shares underlying the Warrant, the Company will be entitled to withhold such taxes in accordance with applicable law; provided,
however, that if Holder provides the Company with a valid certificate of exemption from tax withholding or a determination applying
a reduced withholding tax rate or any other instructions regarding the payment of withholding taxes issued by the Israeli Tax Authority
(each, a “Tax Certificate”), then such withholding (if any) shall be made only in accordance with the provisions of
such Tax Certificate.

 

25.2. Prior
to making any tax withholding payment, the Company shall advise Holder in writing of such proposed payment in order to allow Holder to
present to the Company a Tax Certificate. If any deduction or withholding payment is so made by the Company, then, promptly after paying
any such amount, the Company will furnish Holder with proof reasonably satisfactory to Holder indicating that the Company has made all
such withholding tax payments and remitted such amounts to the applicable tax authority. The Company will cooperate with Holder in connection
with any information and documentation reasonably required by Holder in connection with credits, exemptions, or rebates, or other benefits
to be obtained by Holder in connection with such withholding payments made by the Company, which credits, exemptions, rebates, or other
benefits shall be property of the Holder.

 

 26. Lock Up.

 

The
Holder agrees that in connection with an IPO of the Company, in the event that any lock-up provisions are imposed on the holders of the
same class of shares as that into which this Warrant is exercisable, under any agreement or applicable law, then same lock-up provisions
shall apply in the same manner to the Holder and to any and all shares into which this Warrant is exercisable.

 

[Signature
Page Follows]

 

    13

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Warrant to be executed by their duly authorized representatives effective as of the date
hereof.

 

COMPANY:

 

	Holisto Ltd.	 
	 	 	 
	By:	  	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 
	 	 	 
	 	 	 

 

I,
the undersigned, ___________________________________, the lawyer acting for Holisto Ltd. (the “Company”), hereby confirm
that the above signature composition binds the Company, and that the entry into this Warrant by the Company and the performance thereof
were duly approved by all necessary corporate action in accordance with the law and with the articles of association of the Company.

 

	 	 	 	 	 	 	          ,
Adv.
	Date	 	Name	 	Surname	 	Signature

 

HOLDER:

 

	Discount Capital Ltd.	 
	 	 	 
	By:	    	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 

 

[Signature
Page Warrant]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]